Literature DB >> 12183282

Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitro.

Jean-Sébastien Ripeau1, Francine Aumont, Pierre Belhumeur, Luis Ostrosky-Zeichner, John H Rex, Louis de Repentigny.   

Abstract

Although the echinocandin caspofungin primarily inhibits the synthesis of cell wall 1,3-beta-D-glucan, its fungicidal activity could also potentially perturb the expression of virulence factors involved in the ability of Candida albicans to cause infection. Expression of the C. albicans secretory aspartyl proteinase (SAP) and phospholipase B (PLB) virulence genes was determined by reverse transcription-PCR after the addition of caspofungin to cells grown for 15 h in Sabouraud dextrose broth. In cells that remained viable, expression of SAP1 to SAP3, SAP7 to SAP9, and PLB1 was unaltered after exposure to fungicidal concentrations (4 to 16 micro g/ml) of caspofungin over a period of 7 h. However, expression of SAP5 increased steadily beginning 1 h after exposure to caspofungin. These results indicate that caspofungin is rapidly fungicidal against C. albicans, before any suppression of SAP or PLB1 gene expression can occur.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183282      PMCID: PMC127410          DOI: 10.1128/AAC.46.9.3096-3100.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species.

Authors:  F Barchiesi; A M Schimizzi; A W Fothergill; G Scalise; M G Rinaldi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-04       Impact factor: 3.267

2.  In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis.

Authors:  J R Naglik; G Newport; T C White; L L Fernandes-Naglik; J S Greenspan; D Greenspan; S P Sweet; S J Challacombe; N Agabian
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Determination of a cyclic hexapeptide, a novel antifungal agent, in human plasma by high-performance liquid chromatography with ion spray and turbo ion spray tandem mass spectrometric detection.

Authors:  C M Chavez-Eng; M Schwartz; M L Constanzer; B K Matuszewski
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-01-22

4.  Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors.

Authors:  J Onishi; M Meinz; J Thompson; J Curotto; S Dreikorn; M Rosenbach; C Douglas; G Abruzzo; A Flattery; L Kong; A Cabello; F Vicente; F Pelaez; M T Diez; I Martin; G Bills; R Giacobbe; A Dombrowski; R Schwartz; S Morris; G Harris; A Tsipouras; K Wilson; M B Kurtz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 5.  Potential role of phospholipases in virulence and fungal pathogenesis.

Authors:  M A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

6.  In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods.

Authors:  E J Ernst; M E Klepser; M E Ernst; S A Messer; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  1999-02       Impact factor: 2.803

7.  Evidence for degradation of gastrointestinal mucin by Candida albicans secretory aspartyl proteinase.

Authors:  A R Colina; F Aumont; N Deslauriers; P Belhumeur; L de Repentigny
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

8.  Molecular cloning of a second phospholipase B gene, caPLB2 from Candida albicans.

Authors:  Y Sugiyama; S Nakashima; F Mirbod; H Kanoh; Y Kitajima; M A Ghannoum; Y Nozawa
Journal:  Med Mycol       Date:  1999-02       Impact factor: 4.076

9.  Differential regulation of SAP8 and SAP9, which encode two new members of the secreted aspartic proteinase family in Candida albicans.

Authors:  Michel Monod; Bernhard Hube; Daniela Hess; Dominique Sanglard
Journal:  Microbiology (Reading)       Date:  1998-10       Impact factor: 2.777

10.  Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of Candida albicans.

Authors:  S D Leidich; A S Ibrahim; Y Fu; A Koul; C Jessup; J Vitullo; W Fonzi; F Mirbod; S Nakashima; Y Nozawa; M A Ghannoum
Journal:  J Biol Chem       Date:  1998-10-02       Impact factor: 5.157

View more
  5 in total

1.  Effect of azoles on the secretion of a Candida albicans metallopeptidase.

Authors:  Christine Imbert; Sabrina Imbert-Bouyer; Catherine Kauffmann-Lacroix; Gyslaine Daniault; Marie-Hélène Rodier
Journal:  Mycopathologia       Date:  2006-03       Impact factor: 2.574

Review 2.  Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development.

Authors:  Małgorzata Bondaryk; Wiesław Kurzątkowski; Monika Staniszewska
Journal:  Postepy Dermatol Alergol       Date:  2013-10-30       Impact factor: 1.837

3.  Pneumocystis jirovecii dihydropteroate synthase gene mutations in a group of HIV-negative immunocompromised patients with Pneumocystis pneumonia.

Authors:  Yingjiao Long; Cheng Zhang; Li Su; Chengli Que
Journal:  Exp Ther Med       Date:  2014-10-03       Impact factor: 2.447

4.  Role of Virulence Determinants in Candida albicans' Resistance to Novel 2-bromo-2-chloro-2-(4-chlorophenylsulfonyl)-1-phenylethanone.

Authors:  Monika Staniszewska; Małgorzata Bondaryk; Zbigniew Ochal
Journal:  J Fungi (Basel)       Date:  2017-06-24

Review 5.  Plant-Derived Substances in the Fight Against Infections Caused by Candida Species.

Authors:  Ibeth Guevara-Lora; Grazyna Bras; Justyna Karkowska-Kuleta; Miriam González-González; Kinga Ceballos; Wiktoria Sidlo; Maria Rapala-Kozik
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.